Letter from the editor

Ronald Ellis & Adam Weiss

To cite this article: Ronald Ellis & Adam Weiss (2020) Letter from the editor, Human Vaccines & Immunotherapeutics, 16:1, 1-1, DOI: 10.1080/21645515.2020.1704580

To link to this article: https://doi.org/10.1080/21645515.2020.1704580

Published online: 05 Feb 2020.

Submit your article to this journal

Article views: 105

View related articles

View Crossmark data
EDITORIAL

Letter from the editor

Dear reader,

This issue of Human Vaccines & Therapeutics starts with a Portrait of Dr. Lulu Bravo of the University of the Philippines (Bravo, p 4).

Ten articles on Licensed Vaccines include a review of vaccination in people with disability (O’Neill, p 7), analysis of long-term protection following vaccination with plasma-derived hepatitis B vaccine in China (Ma, p 16), a systematic review of the varicella disease burden in the Middle East (Al Kaabi, p 21), a safety and immunogenicity trial of RTS,S vaccine combined with antimalarial drugs in Thailand (von Seidlein, p 33), a Product Review of the oral cholera vaccine Vaxchora (Saluja, p 42), a study of adherence to guidelines regarding rabies IG utilization (Hwang, p 51), two commentaries on the role of pharmacists in herpes vaccination (Tak, p 70) and countermeasures to vaccine shortages in China (Li, p 76), and a Letter to the Editor on the lessons learned from defective vaccine incidents in China (Fu, p 80).

Research articles on Influenza investigate the impact of promotion programs in seasonal vaccination of health-care workers in Italy (Tognetto, p 81), effect of probiotics on vaccine immunogenicity in subjects with type 1 diabetes (Bianchini, p 86), and decreasing vaccination coverage among adults with chronic diseases in Spain (Martinez-Huedo, p 95).

The Immunotherapy section offers an update on the development of a candidate subunit vaccine for botulinum neurotoxin serotype E (Shi, p 100), and two commentaries on histamine dihydrochloride/IL-2 in acute myeloid leukemia (Nilsson, p 109) and mutational burden as a predictive biomarker for checkpoint inhibition immunotherapy (Lee, p 112).

The HPV segment features a survey of knowledge and attitudes to vaccination among students in China (Liu, p 116), a Letter to the Editor on vaccination in female sex workers (Brown, p 124) with a Response Letter (van der Loeff, p 126), and another Letter to the Editor on vaccination requirements, opt-outs and providers’ support (Calo, p 128) with a Response Letter (Gualano, p 131).

Two articles on Rotavirus report on the decrease in hospitalizations in children after vaccine introduction in Japan (Kobayashi, p 132) and a survey on the role of health-care practitioners in disease and vaccine knowledge (Benninghoff, p 138).

The Hepatitis B section presents a cross-sectional study of risk factors of contracting the disease among vaccinated and unvaccinated people in China (Guo, p 148) and a commentary on the vaccine-at-birth dose in India (Parija, p 158).

Two Pneumococcal-related articles look at the uptake of PCV-13 among immunocompromised U.S. adults (Vietri, p 161) and an immunogenicity and safety of PCV-13 in HIV-infected adults (Song, p 169).

Finally, we introduce a study on uptake of Meningococcal ACYW vaccine in U.S. adults (Cheng, p 176), a Clinical paper on safe sites for intramuscular vaccine administration into the thigh (Nakajima, p 189), and a Novel Vaccines review on functional antibodies for evaluation of immunity against Shigella (Ndungo, p 197).

Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section, we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss (adam.c.weiss@taylorandfrancis.com) with your ideas for commentaries, opinion pieces, profiles, and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!

Sincerely,

Ronald Ellis, PhD
Editor-in-Chief

Adam Weiss, PhD
Acquisitions Editor